Senses Disorder TRIZ Cases

Specific amino acid motifs create smaller human C5-binding polypeptides that block complement without the size of conventional antibodies.

Measuring IL-6 in aqueous humor identifies patients likely to respond to IL-6 antagonist therapy before treatment.

Histidine buffer with trehalose and polysorbate 80 stabilizes soluble gp130 dimers at concentrations up to 30 mg/mL.

Stability and odor challenges in omega-3 topicals are addressed with melatonin, vitamin D3, and optional β-glucan for barrier and inflammation support.

See how a CEP290 minigene omits the M region to fit AAV vectors and restore cilia and photoreceptor function in ocular ciliopathies.

Oral KW3110 bacteria suppress blue-light retinal inflammation, helping protect retinal pigment epithelial cells from death and eye fatigue.

Instead of blocking all γ-secretase activity, these compounds selectively reduce Aβ42 while preserving shorter, less neurotoxic Aβ isoforms.

Hyaluronic acid and an oligosaccharide help retain resveratrol on the ocular surface for longer relief and antioxidant protection.

Frequent DME injections impose patient burden; HRF volume and count guide personalized intervals for bispecific VEGF/ANG2 antibody treatment.

Selective pyrazole compounds target IRAK kinases to address limited pathway-specific inhibition in IRAK-associated diseases.

Sequential culture uses differentiating agents, TGFβ media, cell removal, and adherent expansion to raise RPE yield while reducing labor and time.

Antibody-targeted albumin nanoparticles deliver EDTA or DTPA to calcified Bruch's membrane while limiting chelator toxicity.

Combining IL-11 and angiogenic-factor antagonists addresses ocular fibrosis and angiogenesis where single-target anti-VEGF therapy remains inadequate.

Modified AAV2 capsids address weak delivery and expression in foveal cones by improving nucleic acid transfer across retinal cell types.

Dual prime editors target complementary TCF4 strands to excise pathogenic CTG repeats, addressing FECD’s genetic cause beyond symptom management.

AAV delivery enables retinal cells to produce Factor I, regulate C3b breakdown, and slow geographic atrophy progression in dry AMD.

Frequent anti-VEGF injections burden patients; retinal gene therapy creates a depot for continuous VEGF inhibition.

Point mutations in the P-domain or bulge region improve target hybridization, reduce non-specific binding, and support precise nucleic acid modification.

An IL-11 binding receptor blocks IL-11 interaction with gp130 to suppress fibrosis while avoiding direct TGFβ1 pathway inhibition.

Site-specific amino acid substitutions in AAV2 capsids address low transduction and restricted tropism for ocular cells.

A stabilized VEGFR fusion protein targets multiple angiogenic pathways, preserving potency while reducing vascular leakage.

Existing PDE5 inhibitors such as sildenafil may lack potency and selectivity; pyrrolo triazine compounds show stronger inhibition for cGMP-related therapy.

Amino acid substitutions in AAV capsids reduce heparan sulfate binding and improve therapeutic gene transduction in retinal and CNS cells.

An antibody-targeted biodegradable carrier concentrates anti-calcifying agents at ocular deposits while limiting exposure to healthy tissues.

Soft gel capsules and surfactant excipients stabilize blueberry polyphenols and improve bioavailability for oral dry eye treatment.

A controlled iPSC protocol selects OLIG2+/CD140a+ progenitors, reducing unwanted cell types and supporting efficient myelination.

Metal control and high-pressure homogenization stabilize cannabinoid nanoemulsions for at least 3 months at room temperature.

Novel NK33 and NK98 lactic acid bacteria address stress-related behaviors and inflammation through gut-brain axis activity.

Quillaja saponin emulsifies poorly water-soluble lutein, while ascorbic acid helps limit oxidation and discoloration in water-based foods.

Random iPSC differentiation creates heterogeneous oligodendrocyte preparations; staged induction and CD140a/PDGFRα sorting enrich cells for myelination.

Plasma kallikrein inhibitor compounds target the enzyme to reduce bradykinin generation and help manage debilitating HAE swelling attacks.

Learn how C3 heteroaromatic β-D-galactopyranose compounds resist hydrolysis while binding galectin-1 and galectin-3 with high affinity.

Amniotic and scleral tissue implants are cut and delivered through a cannula to improve aqueous outflow with minimal manipulation.

The iVR1-Cys terminal modification improves VEGFR-1 inhibition and supports oral treatment of angiogenesis-related pathologies.

PIP targets TGF-β and integrin pathways to inhibit or reverse ocular fibrosis, reducing scar formation while supporting wound healing.

Measuring a reduced LH/FSH ratio supports Keratoconus detection, while PIP or GNRH can increase the ratio for treatment.

Inadequate thyroid eye disease therapies are addressed with extended-half-life IGF-1R antibodies that block pathogenic signaling and reduce proptosis.

Anti-C1q antibody blocks the classical complement cascade to limit retinal inflammation and preserve photoreceptor synapses across IRDs.

Benzazepine-family derivatives inhibit NEP and hSEP to address symptomless progressive organ perfusion deficiency before disease symptoms appear.

Substituted phenoxy carboxylic acids regulate glycolipid metabolism while reducing body weight and liver fat in metabolic disease treatment.

Demodex-associated blepharitis has limited safe treatment options; these ophthalmic isoxazoline formulations target mites while reducing ocular irritation.

Limited hearing-loss treatments are addressed with dual-AAV delivery of separate otoferlin coding segments to inner hair cells.

Stage-specific WNT agonists and antagonists balance retinal vascular development and aberrant neovascularization in retinopathy treatment.

Deeper retinal cell types limit current AAV gene delivery; amino-acid-modified capsids improve infectivity and transduction.

Combining VEGFA, VEGFC, and Ang2 binding in one fusion protein addresses pathway coverage while reducing treatment complexity.

15-PGDH inhibitors target short-chain dehydrogenase activity to reduce collagen deposition and inflammatory cytokine expression in fibrotic disease.

Smaller VHH-based bispecific molecules raise molar concentration and strengthen VEGF-A and ANG-2 blocking for less frequent ocular dosing.

Human clinical studies show an L-137 composition can reduce fatigue and insomnia linked to psychological or physical stress.

An uncoupled plunger contacts the stopper to expel ophthalmic fluid while limiting pressure-driven movement that can compromise sterility.

Formula I compounds modify lipophilicity to cross the blood-brain barrier while stimulating sGC and increasing cGMP for CNS disease treatment.